Search
Jul 10, 2024
Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain
CEO William Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients...